Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Priscilla Borrego

Psychiatry Cutler Bay, FL Medical Doctor

NPI 1346231768 CMS profile 106513

10300 Sw 216Th St, Cutler Bay, FL 33190

Open in the dashboard

General payments

$17,208

809 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Priscilla Borrego of Cutler Bay, FL is reported in the CMS Open Payments database as having received $17,208 across 809 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,381 146
2024 General $4,844 156
2023 General $2,951 126
2022 General $1,764 93
2021 General $580 22
2020 General $817 60
2019 General $2,872 206

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priscilla Borrego
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Priscilla Borrego were reported at $3,381. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Priscilla Borrego Psychiatry median Middle half National median
2019 $2,872 $184 $59–$605 $163
2020 $817 $119 $36–$372 $114
2021 $580 $143 $43–$576 $132
2022 $1,764 $153 $50–$590 $149
2023 $2,951 $170 $56–$651 $160
2024 $4,844 $179 $57–$673 $164
2025 $3,381 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,472 120 payments
  2. Teva Pharmaceuticals USA, Inc. $2,581 140 payments
  3. Otsuka America Pharmaceutical, Inc. $2,045 93 payments
  4. Janssen Pharmaceuticals, Inc $1,043 52 payments
  5. Alkermes, Inc. $1,016 47 payments
  6. Sunovion Pharmaceuticals Inc. $972 76 payments
  7. Allergan Inc. $900 57 payments
  8. ITI, Inc. $887 33 payments
  9. Neurocrine Biosciences, Inc. $854 39 payments
  10. Lundbeck LLC $769 40 payments
  11. Other $2,670 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,019 803 payments
  2. Travel and Lodging $1,110 4 payments
  3. Education $80 2 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,987 94 payments
  2. REXULTI Psychiatry $1,284 55 payments
  3. VRAYLAR Neuroscience $1,222 76 payments
  4. AUSTEDO $1,009 86 payments
  5. LATUDA $972 76 payments
  6. Austedo XR $969 42 payments
  7. INVEGA SUSTENNA $864 43 payments
  8. LYBALVI $715 33 payments
  9. REXULTI Psychiatry $715 37 payments
  10. COBENFY $592 19 payments
  11. Other $9,543 432 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

8,618

Median for Psychiatry: 574

Drug cost

$1,224,072

Median for Psychiatry: $27,624

Branded share of claims

12.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 17 $222,821
Austedo Deutetrabenazine Brand 24 $182,889
Ingrezza Valbenazine Tosylate Brand 22 $139,353
Abilify Maintena Aripiprazole Brand 50 $138,765
Aristada Aripiprazole Lauroxil Brand 45 $137,970
Vraylar Cariprazine Hcl Brand 84 $112,443
Invega Sustenna Paliperidone Palmitate Brand 28 $80,490
Rexulti Brexpiprazole Brand 41 $61,831
Trintellix Vortioxetine Hydrobromide Brand 51 $28,035
Aripiprazole Generic 259 $19,731

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$658 41 —
VRAYLAR
$578 84 —
Austedo XR
$480 41 —
INVEGA SUSTENNA
$363 28 —
INGREZZA
$253 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

809 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record